Report Thumbnail
Product Code LP0914810472RS0
Published Date 2023/2/23
English100 PagesGlobal

Global Cancer Biopsy Instruments and Kits Market Growth 2023-2029MedicalDevice_MedTech Market


Report Thumbnail
Product Code LP0914810472RS0◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/23
English 100 PagesGlobal

Global Cancer Biopsy Instruments and Kits Market Growth 2023-2029MedicalDevice_MedTech Market



Abstract


Summary

LPI (LP Information)' newest research report, the “Cancer Biopsy Instruments and Kits Industry Forecast” looks at past sales and reviews total world Cancer Biopsy Instruments and Kits sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Biopsy Instruments and Kits sales for 2023 through 2029. With Cancer Biopsy Instruments and Kits sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Biopsy Instruments and Kits industry.
This Insight Report provides a comprehensive analysis of the global Cancer Biopsy Instruments and Kits landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Biopsy Instruments and Kits portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Biopsy Instruments and Kits market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Biopsy Instruments and Kits and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Biopsy Instruments and Kits.
The global Cancer Biopsy Instruments and Kits market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Biopsy Instruments and Kits is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Biopsy Instruments and Kits is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Biopsy Instruments and Kits is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Biopsy Instruments and Kits players cover QIAGEN NV, Illumina, Inc., Becton, Dickinson and Company, Myriad Genetics, Thermo Fisher Scientific, Inc., BIOCEPT, INC., ANGLE plc, Hologic, Inc. and Lucence Diagnostics Pte. Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Biopsy Instruments and Kits market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Cancer Biopsy Instruments
Cancer Biopsy Kits
Segmentation by application
Breast Cancer
Colorectal Cancer
Cervical Cancer
Lung Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QIAGEN NV
Illumina, Inc.
Becton, Dickinson and Company
Myriad Genetics
Thermo Fisher Scientific, Inc.
BIOCEPT, INC.
ANGLE plc
Hologic, Inc.
Lucence Diagnostics Pte. Ltd.
Danaher Corporation
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cancer Biopsy Instruments and Kits market?
What factors are driving Cancer Biopsy Instruments and Kits market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Biopsy Instruments and Kits market opportunities vary by end market size?
How does Cancer Biopsy Instruments and Kits break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Cancer Biopsy Instruments and Kits Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Cancer Biopsy Instruments and Kits by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Cancer Biopsy Instruments and Kits by Country/Region, 2018, 2022 & 2029
    • 2.2 Cancer Biopsy Instruments and Kits Segment by Type
      • 2.2.1 Cancer Biopsy Instruments
      • 2.2.2 Cancer Biopsy Kits
    • 2.3 Cancer Biopsy Instruments and Kits Sales by Type
      • 2.3.1 Global Cancer Biopsy Instruments and Kits Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Cancer Biopsy Instruments and Kits Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Cancer Biopsy Instruments and Kits Sale Price by Type (2018-2023)
    • 2.4 Cancer Biopsy Instruments and Kits Segment by Application
      • 2.4.1 Breast Cancer
      • 2.4.2 Colorectal Cancer
      • 2.4.3 Cervical Cancer
      • 2.4.4 Lung Cancer
      • 2.4.5 Others
    • 2.5 Cancer Biopsy Instruments and Kits Sales by Application
      • 2.5.1 Global Cancer Biopsy Instruments and Kits Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Cancer Biopsy Instruments and Kits Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Cancer Biopsy Instruments and Kits Sale Price by Application (2018-2023)
  • 3 Global Cancer Biopsy Instruments and Kits by Company

    • 3.1 Global Cancer Biopsy Instruments and Kits Breakdown Data by Company
      • 3.1.1 Global Cancer Biopsy Instruments and Kits Annual Sales by Company (2018-2023)
      • 3.1.2 Global Cancer Biopsy Instruments and Kits Sales Market Share by Company (2018-2023)
    • 3.2 Global Cancer Biopsy Instruments and Kits Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Cancer Biopsy Instruments and Kits Revenue by Company (2018-2023)
      • 3.2.2 Global Cancer Biopsy Instruments and Kits Revenue Market Share by Company (2018-2023)
    • 3.3 Global Cancer Biopsy Instruments and Kits Sale Price by Company
    • 3.4 Key Manufacturers Cancer Biopsy Instruments and Kits Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Cancer Biopsy Instruments and Kits Product Location Distribution
      • 3.4.2 Players Cancer Biopsy Instruments and Kits Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Cancer Biopsy Instruments and Kits by Geographic Region

    • 4.1 World Historic Cancer Biopsy Instruments and Kits Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Cancer Biopsy Instruments and Kits Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Cancer Biopsy Instruments and Kits Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Cancer Biopsy Instruments and Kits Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Cancer Biopsy Instruments and Kits Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Cancer Biopsy Instruments and Kits Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Cancer Biopsy Instruments and Kits Sales Growth
    • 4.4 APAC Cancer Biopsy Instruments and Kits Sales Growth
    • 4.5 Europe Cancer Biopsy Instruments and Kits Sales Growth
    • 4.6 Middle East & Africa Cancer Biopsy Instruments and Kits Sales Growth
  • 5 Americas

    • 5.1 Americas Cancer Biopsy Instruments and Kits Sales by Country
      • 5.1.1 Americas Cancer Biopsy Instruments and Kits Sales by Country (2018-2023)
      • 5.1.2 Americas Cancer Biopsy Instruments and Kits Revenue by Country (2018-2023)
    • 5.2 Americas Cancer Biopsy Instruments and Kits Sales by Type
    • 5.3 Americas Cancer Biopsy Instruments and Kits Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Cancer Biopsy Instruments and Kits Sales by Region
      • 6.1.1 APAC Cancer Biopsy Instruments and Kits Sales by Region (2018-2023)
      • 6.1.2 APAC Cancer Biopsy Instruments and Kits Revenue by Region (2018-2023)
    • 6.2 APAC Cancer Biopsy Instruments and Kits Sales by Type
    • 6.3 APAC Cancer Biopsy Instruments and Kits Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Cancer Biopsy Instruments and Kits by Country
      • 7.1.1 Europe Cancer Biopsy Instruments and Kits Sales by Country (2018-2023)
      • 7.1.2 Europe Cancer Biopsy Instruments and Kits Revenue by Country (2018-2023)
    • 7.2 Europe Cancer Biopsy Instruments and Kits Sales by Type
    • 7.3 Europe Cancer Biopsy Instruments and Kits Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Cancer Biopsy Instruments and Kits by Country
      • 8.1.1 Middle East & Africa Cancer Biopsy Instruments and Kits Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Cancer Biopsy Instruments and Kits Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Cancer Biopsy Instruments and Kits Sales by Type
    • 8.3 Middle East & Africa Cancer Biopsy Instruments and Kits Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Cancer Biopsy Instruments and Kits
    • 10.3 Manufacturing Process Analysis of Cancer Biopsy Instruments and Kits
    • 10.4 Industry Chain Structure of Cancer Biopsy Instruments and Kits
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Cancer Biopsy Instruments and Kits Distributors
    • 11.3 Cancer Biopsy Instruments and Kits Customer
  • 12 World Forecast Review for Cancer Biopsy Instruments and Kits by Geographic Region

    • 12.1 Global Cancer Biopsy Instruments and Kits Market Size Forecast by Region
      • 12.1.1 Global Cancer Biopsy Instruments and Kits Forecast by Region (2024-2029)
      • 12.1.2 Global Cancer Biopsy Instruments and Kits Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Cancer Biopsy Instruments and Kits Forecast by Type
    • 12.7 Global Cancer Biopsy Instruments and Kits Forecast by Application
  • 13 Key Players Analysis

    • 13.1 QIAGEN NV
      • 13.1.1 QIAGEN NV Company Information
      • 13.1.2 QIAGEN NV Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.1.3 QIAGEN NV Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 QIAGEN NV Main Business Overview
      • 13.1.5 QIAGEN NV Latest Developments
    • 13.2 Illumina, Inc.
      • 13.2.1 Illumina, Inc. Company Information
      • 13.2.2 Illumina, Inc. Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.2.3 Illumina, Inc. Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Illumina, Inc. Main Business Overview
      • 13.2.5 Illumina, Inc. Latest Developments
    • 13.3 Becton, Dickinson and Company
      • 13.3.1 Becton, Dickinson and Company Company Information
      • 13.3.2 Becton, Dickinson and Company Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.3.3 Becton, Dickinson and Company Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Becton, Dickinson and Company Main Business Overview
      • 13.3.5 Becton, Dickinson and Company Latest Developments
    • 13.4 Myriad Genetics
      • 13.4.1 Myriad Genetics Company Information
      • 13.4.2 Myriad Genetics Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.4.3 Myriad Genetics Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Myriad Genetics Main Business Overview
      • 13.4.5 Myriad Genetics Latest Developments
    • 13.5 Thermo Fisher Scientific, Inc.
      • 13.5.1 Thermo Fisher Scientific, Inc. Company Information
      • 13.5.2 Thermo Fisher Scientific, Inc. Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.5.3 Thermo Fisher Scientific, Inc. Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Thermo Fisher Scientific, Inc. Main Business Overview
      • 13.5.5 Thermo Fisher Scientific, Inc. Latest Developments
    • 13.6 BIOCEPT, INC.
      • 13.6.1 BIOCEPT, INC. Company Information
      • 13.6.2 BIOCEPT, INC. Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.6.3 BIOCEPT, INC. Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 BIOCEPT, INC. Main Business Overview
      • 13.6.5 BIOCEPT, INC. Latest Developments
    • 13.7 ANGLE plc
      • 13.7.1 ANGLE plc Company Information
      • 13.7.2 ANGLE plc Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.7.3 ANGLE plc Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 ANGLE plc Main Business Overview
      • 13.7.5 ANGLE plc Latest Developments
    • 13.8 Hologic, Inc.
      • 13.8.1 Hologic, Inc. Company Information
      • 13.8.2 Hologic, Inc. Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.8.3 Hologic, Inc. Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Hologic, Inc. Main Business Overview
      • 13.8.5 Hologic, Inc. Latest Developments
    • 13.9 Lucence Diagnostics Pte. Ltd.
      • 13.9.1 Lucence Diagnostics Pte. Ltd. Company Information
      • 13.9.2 Lucence Diagnostics Pte. Ltd. Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.9.3 Lucence Diagnostics Pte. Ltd. Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 Lucence Diagnostics Pte. Ltd. Main Business Overview
      • 13.9.5 Lucence Diagnostics Pte. Ltd. Latest Developments
    • 13.10 Danaher Corporation
      • 13.10.1 Danaher Corporation Company Information
      • 13.10.2 Danaher Corporation Cancer Biopsy Instruments and Kits Product Portfolios and Specifications
      • 13.10.3 Danaher Corporation Cancer Biopsy Instruments and Kits Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Danaher Corporation Main Business Overview
      • 13.10.5 Danaher Corporation Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.